You are here: Home » Companies » News
Business Standard

More trouble for Ranbaxy as drug boycott to continue

BS Reporter  |  New Delhi 

After the US and Indian authorities, the medicines manufactured by Ranbaxy Laboratories are now under the scanner of hospitals, too. Mumbai's leading Jaslok Hospital has already put up a notice advising its doctors to avoid prescribing Ranbaxy drugs, while some others are reviewing the matter. Medanta Medicity officials say they will soon assess the situation and take a decision.

"I have received around a dozen queries from patients recently. They want to check if there is any alternative to Ranbaxy medicines that they are taking currently… I think we will discuss this tomorrow and review what needs to be done," Medanta Chairman and Managing Director Naresh Trehan said.

A senior official of Apollo Hospitals told Business Standard it was reviewing the situation and would take action, if necessary. The hospital hasn't issued an advisory so far.

"We will be able to give you some update tomorrow," said a senior official at Breach Candy, another leading Mumbai hospital.

Sources said Jaslok Hospital put up the notice four days ago, saying Ranbaxy medicines would not be available at the hospital and doctors should, as far as possible, not prescribe these drugs. The hospital has, however, not specified any reason. Phone calls and messages sent to Jaslok CEO R R Pulgaonkar remained unanswered.

The move has come a fortnight after Ranbaxy pleaded guilty in the US to making fraudulent statements to the US drug regulator about testing drugs. The company also agreed to pay a $500-million penalty to authorities there.

If more hospitals decide to stop prescribing Ranbaxy medicines, the trouble for the company might intensify, pulling down its sales in some of its major markets in the quarters to come.

When contacted, a Ranbaxy spokesperson refused to offer comments.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, May 29 2013. 00:58 IST
RECOMMENDED FOR YOU
.